Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Hypertensive Heart Disease Clinical Trial

— REVERSE-LVH  

Official title:

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03553810
• Other study ID #: 2018/2182
• Status: Recruiting
• Phase: Phase 2
• Start date: April 12, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: May 2023
• Source: National Heart Centre Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Singapore, hypertension is very common in the adult population. Hypertensive heart disease is a leading cause of heart failure and cardiovascular death. Current management relies primarily on achieving blood pressure targets. However, the optimal blood pressure goals are controversial and there are inherent difficulties in measuring blood pressure using external devices applied to peripheral arteries. As a result of (usually longstanding) hypertension, the heart thickens (i.e. hypertrophies) to maintain function. Ultimately, HF may occur due to long standing energy deficits, muscle injury/death and diffuse interstitial fibrosis (heart muscle scarring). In an ongoing study (REMODEL, ClinicalTrial.gov Identifier NCT02670031), we have been able to undertake preliminary analyses with respect to factors associated with the development of fibrosis. In this randomize controlled trial, we will be examining a novel therapy that has the potential to induce regression cardiac hypertrophy and fibrosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 31, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 99 Years

Eligibility

Inclusion Criteria:

• Increased left ventricular mass on cardiovascular magnetic resonance (based on established local age- and sex-specific CMR ranges)
• Essential hypertension

Exclusion Criteria:

• Known secondary causes of hypertension
• Previous intolerance to angiotensin receptor blockers
• History of heart failure
• Stage IV/V chronic renal disease (eGFR < 30ml/min/1.73m2)
• Patients with serum potassium > 5.2 mmol/L (mEg/L) at Visit 1
• History of cardiovascular events (myocardial infarction, strokes and transient ischemic attacks)
• Known atrial fibrillation
• Being unable to understand or comply with study procedures (including CMR)
• History or presence of any other disease with a life expectancy of < 3 years
• Pregnant or nursing (lactating) women

Related Conditions & MeSH terms

• Heart Diseases
• Hypertensive Heart Disease
• Ventricular Remodeling

Intervention

Drug:
• Entresto
Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
• Valsartan
Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.

Locations

Country	Name	City	State
Singapore	National Heart Centre Singapore	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
National Heart Centre Singapore	National Medical Research Council (NMRC), Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fibrosis volume	A difference in terms of change in interstitial volume from baseline following 52 weeks of treatment. Extracellular volume fraction (ECV) will be quantified from native and post-contrast myocardial T1. Fibrosis volume is defined as ECV x myocardial volume and indexed to body surface area (ml/m2)	52 weeks
Secondary	Left ventricular mass measured on CMR	Changes from baseline in left ventricular mass, indexed to body surface area (g/m2).	52 weeks
Secondary	Biomarker/biochemistry	Identify potential markers as indicators of cardiac structural effects of ARNi and ARB	52 weeks